Table 1 Mice initial body weights and change in body weight in different experimental groups.

From: Amygdalin potentiates the anti-cancer effect of Sorafenib on Ehrlich ascites carcinoma and ameliorates the associated liver damage

Groups

Initial body weight (g)

Body weight change (g)

Cnt

20.25 ± 0.75

4.26 ± 0.33b

Amy

21.47 ± 0.67

2.75 ± 0.12c

SorIP

21.75 ± 0.85

− 7.23 ± 0.41f

SorOS

20.75 ± 0.65

− 8.28 ± 0.60f

Amy + SorIP

21.31 ± 0.71

2.25 ± 0.12c

Amy + SorOS

21.00 ± 0.40

− 4.22 ± 0.45e

EAC

20.48 ± 0.63

7.53 ± 0.92a

EAC + Amy

21.63 ± 0.55

4.62 ± 0.46b

EAC + SorIP

21.26 ± 0.40

− 3.75 ± 0.30e

EAC + SorOS

20.60 ± 0.85

− 3.52 ± 0.31e

EAC + Amy + SorIP

21.50 ± 0.69

− 0.24 ± 0.10d

EAC + Amy + SorOS

21.06 ± 0.41

− 2.87 ± 0.12e

  1. Data were presented as means ± SEM. Small (a–f) letters showed the marked change at P ≤ 0.05. The significant were expressed by dissimilar letters in the same column. Cnt Control, Amy Amygdalin, Sor Sorafenib, EAC Ehrlich ascetic carcinoma, IP Intraperitoneal, OS Per os (oral).
Back to article page